172results about How to "High binding activity" patented technology

Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the effector function of monoclonal antibodies and monoclonal antibodies with increased effector function.

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15Rα) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15Rα domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.

The invention discloses an anti-human CLDN18.2 antibody as well as an antigen binding fragment and a medical application thereof. Specifically, the present invention relates to a murine antibody comprising a CDR region of the anti-human CLDN18.2 antibody, a chimeric antibody and a humanized antibody, a fully humanized antibody, an antibody-dependent cytotoxicity (ADCC) comprising the antibody andthe antigen binding fragment thereof, complement dependent cytotoxicity (CDC), the killing effect on CLDN18.2 positive cells, the effect of inhibiting the growth of CLDN18.2 positive tumors, the in-vivo drug effect, a medicine containing the anti-human CLDN18.2 antibody and the antigen binding fragment thereof, a composition of the medicine thereof, and an application of the medicine in tumor treatment, in particular to treatment of CLDN18.2 positive tumor patients..

The invention belongs to the field of medicine, and relates to D-configuration polypeptide with high stability and capable of realizing mediated targeting of acetylcholine receptor high-expression cells and crossing corresponding barrier membranes and a nano drug delivery system thereof as well as an application in in-vivo and in-vitro brain targeting and in treatment of brain diseases and the like. Test results indicate that DCDX and the acetylcholine receptor are combined with IC50 to obtain 84.5nM which is stable in serum and tolerates hydrolysis of protease; the model drug carried by DCDX is specifically taken in by the positive cells expressing the acetylcholine receptor and has an ability of crossing the barrier formed by the kind of cells; and the nano drug delivery system made of a DCDX-modified polymer carrier material can deliver the entrapped model drug to the target tissue while the drug effect is remarkably improved. The D-configuration polypeptide DCDX provided by the invention can mediate active targeting of the drug or nano drug delivery system and has a good application prospect in the diagnosis and treatment of multiple diseases.

The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor alpha (PPARalpha), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride).It relates to a substituted phenylpropanoic acid derivatives represented by a general formula (1),their pharmaceutically acceptable salts and their hydrates, and processes for preparing them.

In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sickle-cell disease or one or more complications associated with sickle-cell disease.

The invention belongs to the field of pharmacy and relates to a D-configuration polypeptide and a gene delivery system of the D-configuration polypeptide and particularly relates to the D-configuration polypeptide which has high combining activity with neuropilin NRP-1 and has the brain tumor targeting and tumor tissue penetrating capabilities. The D-configuration polypeptide provided by the invention can mediate a nano delivery system to deliver drugs to tumors in a targeted manner for realizing targeted treatment of brain in-situ glioma. In vivo and in vitro experiments show that the genetic vector modified by the D-configuration polypeptide can remarkably improve the gene transfection efficiency. The genetic vector entrapping the therapeutic gene pORF-hTRAIL can remarkably prolong the lifetime of a nude mouse of brain glioma in-situ mode.

The present invention discloses an antibody drug conjugate of a CLDN 18.2-resistant antibody. The structure of the antibody drug conjugate (ADC) is shown as Ab-[(L2)n-L1-D]y in a formula I, wherein Dis a small-molecule cytotoxic drug, L1 and L2 are connected to the drug and the antibody separately, and n is 0 or 1; y represents the average number of D which is coupled to Ab, 0 < y <= 10, and Ab is an antibody which can be specifically bound to human CLDN 18.2, and includes a light-chain variable region (VL) and/or a heavy-chain variable region (VH); and the CLDN 18.2-resistant antibody correspondingly contains at least one specific complementary determining region (CDR) sequence or a mutant sequence of the specific complementary determining region (CDR) sequence in the light-chain variable region (VL) and/or a heavy-chain variable region (VH), and binding of the antibody to CLDN 18.2 is maintained or improved through the mutation. The invention also discloses a ADC-containing pharmaceutical composition and a preparation method and application of ADC. The antibody drug conjugate of the antibody has a large security window and low toxic and side effects, and provides more specific,more effective and better treatment option for tumor patients.

The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.

A nucleic acid delivery system is described. The delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a ligand. The use of this nucleic acid delivery system to transienntly or stably express a desired nucleic acid sequence in a cell is disclosed. Also disclosed is the use of this delivery system to target a cell and deliver a desired product.

The invention belongs to the field of antibodies, and more particularly relates to a preparation method and applications of a monoclonal antibody against human CD47. The invention discloses the heightvariable region sequence of the monoclonal antibody. The monoclonal antibody against the human CD47 provided by the invention has good binding activity, can effectively recognize the expression of CD47 on the surfaces of tumor cells, and can effectively recognize the extracellular domain recombinant protein of the human CD47 at the protein level. In addition, the antigen epitope identification ofthe monoclonal antibody is clear, thereby being effectively applied to the diagnosis of CD47 target molecules and preparation and development of monoclonal antibody drugs against the human CD47.

The invention discloses a chimeric T cell receptor STAR (Synthetic T Cell Receptor and Antigen Receptor), related preparations and drugs, and application of the chimeric T cell receptor STAR in preparation of cell drugs, and also relates to the preparation or an drug composition used for treatment of corresponding diseases such as tumors or infectious diseases.

The invention relates to a dental prosthetic material for promoting dentin remineralization. The dental prosthetic material for promoting dentin remineralization contains a polypeptide solution and a nanometer amorphous calcium phosphate suspension which are successively applied to the surface of a dentin surface, wherein the polypeptide solution and the nanometer amorphous calcium phosphate suspension are physically isolated before use; the polypeptide solution contains polypeptide and water, wherein the polypeptide has functions of adsorbing calcium ions and binding to type I collagen, and the polypeptide has a concentration of 0.5 to 0. 8 mg/ml; the nanometer amorphous calcium phosphate suspension contains nanometer amorphous calcium phosphate and water, wherein the concentration of nanometer amorphous calcium phosphate is 0.2 to 0.3 g/ml. The parental function polypeptide is combined with the nanometer amorphous calcium phosphate to be used, and the nanometer amorphous calcium phosphate can effectively realize the in situ remineralization on the dentin, with high degree of mineralization and bionic degree by setting the appropriate concentration ratio.

In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.

The invention discloses a bispecific antibody and an application thereof. Wherein the bispecific antibody comprises a first protein functional area and a second protein functional area; wherein the first protein functional area is the protein functional area targeting TIM-3; the TIM-3 full-length antibody of the targeting TIM-3 corresponding to the first protein functional area has weak binding activity with macaca TIM-3, has strong binding activity with marmoset and human TIM-3, and can activate the killing effect of human NK cells on tumor cells. The bispecific antibody not only can retain the activity of activating PBMC (NK) to kill tumor cells of the single TIM-3 antibody, but also can retain the original activity of the other protein functional area, and can achieve the activity equivalent to or better than the activity of activating T lymphocytes by combining two molecules (synergistic effect). The bispecific antibody (e.g., LB141) of the present invention has a more excellent effect in therapy than PD-1 antibody treatment alone or combined use of the TIM-3 antibody and the PD-1 antibody.

The invention discloses an antibody, and a coding gene and application thereof. An amino acid sequence of a heavy chain variable region of the antibody is shown in the sequence 2 in a sequence table, while the amino acid sequence of a light chain is shown in the sequence 3 in the sequence table. Experimental results prove that the antibody of the invention has high binding activity (affinity is 2.7*10-8 mol/L) and high tumor cell growth and migration suppression capacity; and the affinity of an anti-epidermal growth factor receptor (EGFR) human-mouse chimeric antibody Cetuximab in foreign markets is 1.1*10-9 M. The humanized antibody of the invention can be better bound with an EGFR so as to ensure anti-tumor effect thereof. An anti-body preparation method of the invention has the advantage of simultaneously expressing the light chain and the heavy chain variable region. After all, the antibody and the preparation method thereof have vast application prospect in the field of the prevention and/or treatment of tumors.

The invention relates to a method for producing recombinant protein A, which belongs to the technical field of biological engineering and provides a technological condition for fermenting and expressing the recombinant protein A in high density by using genetic engineering bacteria, and a method for separating and purifying the recombinant protein A in high purity by using Fc segment of IgG as anaffinity ligand by a one-step affinity chromatography method. By applying the method for producing the recombinant protein A, the culture density of the recombinant bacteria fermented in high densityreaches OD600nm=80-100; the dry weight of the bacteria is 40-50g/L; the expression quantity of the protein A occupies 30% to 50% of total protein of the bacteria; the quantity of the protein A produced by each liter of bacterial liquid reaches 3g; and the purity of the protein A detected by SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) and HPLC (High Performance Liquid Chromatography) is more than 95%. The method has the advantages of large yield, low cost, high product quality, and the like, and provides a practicable approach for preparing the recombinant protein A.

The present invention provides a peptide capable of specifically binding to human IgG. In particular, the present invention relates to a human IgG binding peptide tag of 11 to 16 amino acids in length, comprising at least an amino acid sequence of the formula I:

wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula I contains no cysteine residue, and

wherein said amino acid sequence satisfies either or both of a) and b):

• • a) (X)_n—W in the formula I denotes Za-G-Y—W (SEQ ID NO: 18); and
  • b) W—(X)_m in the formula I denotes W-G-L-Zb (SEQ ID NO: 19)

wherein Za and Zb are each 0, 1, or more amino acid residues.